UBE2O-RNF213 Fusion FISH Probe
The UBE2O-RNF213 Fusion FISH Probe is used to confirm a fusion of the UBE2O and RNF213 genes. The fusion of the UBE2O and RNF213 genes has been associated with Breast Invasive Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| UBE2O-RNF213-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-RERE | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-REOR | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-REGO | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-REGR | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-OROR | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GORE | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GROR | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| UBE2O-RNF213-20-AQAQ | 20 (40 μL) | 200 μL |
|
RNF213 Gene Summary
This gene encodes a protein containing a C3HC4-type RING finger domain, which is a specialized type of Zn-finger that binds two atoms of zinc and is thought to be involved in mediating protein-protein interactions. The protein also contains an AAA domain, which is associated with ATPase activity. This gene is a susceptibility gene for Moyamoya disease, a vascular disorder of intracranial arteries. This gene is also a translocation partner in anaplastic large cell lymphoma and inflammatory myofibroblastic tumor cases, where a t(2;17)(p23;q25) translocation has been identified with the anaplastic lymphoma kinase (ALK) gene on chromosome 2, and a t(8;17)(q24;q25) translocation has been identified with the MYC gene on chromosome 8. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2011]
Gene Name: Ring Finger Protein 213
Chromosome: CHR17: 78234666 -78370086
Locus: 17q25.3
UBE2O Gene Summary
The Ubiquitin Conjugating Enzyme E2 O (UBE2O) gene is located on chr17 :74385612-74449288 at 17q25.1.
Gene Name: Ubiquitin Conjugating Enzyme E2 O
Chromosome: CHR17: 74385612 -74449288
Locus: 17q25.1
Gene Diseases
The UBE2O RNF213 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Breast Invasive Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|